45 serum samples after CAR-T treatment analysis by proteomic and validate by PRM
收藏integrated proteome resources2026-02-07 收录
官方服务：
资源简介：
45 serum samples after CAR-T treatment analysis by proteomic and validate by PRM
应用场景：
提供机构：
Westlake UUniversity创建时间：
2024-04-07
相关数据集
Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I. Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I
Alternate strategies are needed for B-cell malignancy patients relapsing after CD19-targeted immunotherapy. Here, integrated cell surface proteomics and epigenetic analysis initially revealed CD72 as
NIAID Data Ecosystem180
Overlap analysis of the top differentially expressed proteins identified via 2D-PAGE and LC-MS/MS analysis, differentially expressed transcripts, and significantly affected proteins from previous proteomic studies.
Overlap analysis of the top differentially expressed proteins identified via 2D-PAGE and LC-MS/MS analysis, differentially expressed transcripts, and significantly affected proteins from previous prot
NIAID Data Ecosystem50
Validating Missing Proteins in Human Sperm Cells by Targeted Mass-Spectrometry- and Antibody-based Methods
The present study is a contribution to the “neXt50 challenge”, a coordinated effort across C-HPP teams to identify the 50 most tractable missing proteins (MPs) on each chromosome. We report the target
NIAID Data Ecosystem40
Validation of 14 selected protein biomarkers in patients and healthy controls.
Validation was done by dot blot assay with the specific antibodies on single PBMC samples from ALS patients, ALS>24 (n = 30) and ALS≤24 (n = 30), and healthy controls (n = 30); mean ± SD of the relati
Figshare2015-12-02 更新70
Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc
PurposeCD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS)
NIAID Data Ecosystem40
